Neumora Therapeutics (NMRA) director granted 80,000 stock options at $1.86

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. director Alaa Halawa received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 option shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Halawa Alaa

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	80,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 80,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 80,000 shares Exercise price: $1.86 per share Total options after grant: 80,000 options +3 more

6 metrics

Option shares granted 80,000 shares Stock Option (Right to Buy) grant to director

Exercise price $1.86 per share Conversion or exercise price of the option

Total options after grant 80,000 options Total derivative securities following transaction

Expiration date May 26, 2036 Option expiration

Underlying common stock 80,000 shares Underlying security for the option

Vesting trigger date reference May 27, 2026 Used to define one-year anniversary vesting condition

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, Annual Meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "1.8600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting regulatory

"immediately prior to the next Annual Meeting following May 27, 2026."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

derivative securities financial

"derivativeTransactionCount for derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Halawa Alaa

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.86	05/27/2026		A		80,000		(1)	05/26/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

	/s/ Michael Milligan, as Attorney-in-Fact for Alaa Halawa	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neumora Therapeutics (NMRA) report for Alaa Halawa?

Neumora Therapeutics reported that director Alaa Halawa received a grant of stock options for 80,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale, and reflects equity-based pay for board service.

What is the exercise price of Alaa Halawa’s new options at Neumora Therapeutics (NMRA)?

The granted stock options to director Alaa Halawa have an exercise price of $1.86 per share. This means Halawa can purchase Neumora common stock at $1.86 per share once the options vest and are exercised, subject to the option terms.

When do Alaa Halawa’s Neumora Therapeutics (NMRA) options vest?

All 80,000 option shares vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date. This single-vesting schedule ties the award to continued board service through that milestone.

When do Alaa Halawa’s Neumora Therapeutics (NMRA) options expire?

The stock options granted to director Alaa Halawa expire on May 26, 2036. After that expiration date, any unexercised options become worthless, so potential value must be realized by exercising before expiration, subject to vesting and other conditions.

Is Alaa Halawa’s Form 4 transaction in Neumora Therapeutics (NMRA) a buy or a grant?

The Form 4 reports a grant/award acquisition of stock options, not an open-market buy. Transaction code “A” indicates a compensation-related award, with 80,000 option shares acquired at a stated exercise price, rather than shares purchased on the market.